New Project Application
If you are interested in submitting a project partnership idea to the CCEIP Board, please complete the application above. You can return this completed form to email@example.com.
When assessing the success of a certain pharmacologic treatment for a patient with schizophrenia, there is a distinction to be made between “efficacy” and “effectiveness”. The Canadian Consortium for Early Intervention in Psychosis has created a clinical definition for ‘treatment effectiveness’ based on a sound conceptual framework, currently available evidence and clinical experience. This definition will assist clinicians in evaluating an effective response to treatment which will incorporate efficacy, tolerability and acceptance.
This conceptual framework was created by a national faculty and reviewed by our membership. A slide deck has been developed (see below).
M191 - CCEIP Clinical Effectiveness_Final v2
- Project Lead: Dr. Ashok Malla
- Project Sponsor: Otsuka/Lundbeck Alliance
While relapse is considered an almost inevitable event in the course of psychotic disorders, it does have enormous consequences for the patient, his/her family and society. First of all, a relapse of psychosis after a period of improvement (remission) can be extremely discouraging and demoralizing to the patient and their family. It may carry the message to the patient of a recurring and chronic illness, causing an erosion of hope for the future. During a relapse a patient is once again at risk of behaviour that may be dangerous to him or herself and towards others. Therefore, it is very desirable if a relapse can be prevented, especially during the early course of illness. The CCEIP is currently developing a relapse risk assessment for use by clinicians and caregivers. Please see below to see the poster results and executive summary of our qualitative research which will help inform the design of the tool.
The SEPRRA tool has been assessed for feasibility and reliability, but before it can be used in routine clinical practice, the validity must be evaluated. If your clinic is interested in participating in the validation of this important tool, please reach out to Megan Connolly at firstname.lastname@example.org
for more details.
- Project Lead: Ashok Malla
- Project Sponsors: Schizophrenia Society of Canada Foundation and Otsuka-Lundbeck Alliance
There is consistent and abundant evidence that clozapine is effective in treatment-resistant schizophrenia compared to all other first or second generation antipsychotic agents.
The Canadian Consortium for Early Intervention in Psychosis will be evaluating the profile of clozapine use within the first two years of diagnosis of non-affective psychosis.
- Project Lead: Dr. Richard Williams
- Project Sponsor: Mylan Pharmaceuticals
Early intervention for psychosis programs (EIPP) have been implemented in Canada without national standards of care. Other countries have developed clinical guidelines, and literature highlights several elements considered as essential. Investigations in other countries have described slow implementation of services and the frequent absence of important components. The Canadian Consortium for Early Intervention in Psychosis was formed in 2012 : one of its objectives being the development of standards of care, better knowledge of Canadian practices was needed. An on-line benchmark survey was administered in 2013 to 11 academic FEP clinics in Canada. Questions covered administrative, clinical, education and research topics.
Schizophrenia and use of antipsychotics are independently associated with increased motor and metabolic abnormalities, which can contribute to non-adherence to medication, and increased morbidity and mortality. The CCEIP has developed a one-page clinical assessment tool for monitoring these potential side effects along with a corresponding video.
- Project Lead: Dr. Tom Hastings
- Project Sponsor: Janssen Inc